Search Results
FDA Approvals in Bladder Cancer, NSCLC, AML, HCC, and a Breakthrough Designation in NSCLC
FDA Approvals in Bladder Cancer and Hodgkin Lymphoma, Breakthrough Designation in AML, and More
FDA Approvals in Breast Cancer and NSCLC, NDA Accepted in HCC, and More
FDA Approvals in ALL, Ovarian Cancer, Priority Review in CTCL, and sNDA Submitted in RCC
FDA Approvals in Breast Cancer and Bladder Cancer and Phase III Data With Larotrectinib
Breakthrough E-selectin inhibitor therapy for elderly AML
Breakthrough Designation in AML, Trials Halted in Head and Neck Cancer, and More
Evidence in the HCC Adjuvant Setting
FDA Approvals in Follicular Lymphoma and Prostate Cancer, Biosimilar Is Granted Approval, and More
Dr. Grivas on Investigational Immunotherapy Approaches in Localized Bladder Cancer
Dr. Plimack on Choosing a Checkpoint Inhibitor in Bladder Cancer
Advancing Bladder Cancer Care With Novel Therapeutics